Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
News|Articles|July 11, 2025
Are You Ready for the Southern California Psychiatry Conference?
Author(s)Leah Kuntz
Brush up on your reading before you attend the Southern California Psychiatry Conference!
Related to this article
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
5